ID   GLC-4/CDDP
AC   CVCL_4998
SY   GLC4-CDDP; GLC4/CDDP; GLC4/cDDP
DR   BTO; BTO:0002388
DR   cancercelllines; CVCL_4998
DR   Cosmic; 1998275
DR   GEO; GSM536325
DR   Progenetix; CVCL_4998
DR   Wikidata; Q54835915
RX   PubMed=1657425;
RX   PubMed=2163989;
RX   PubMed=2846161;
RX   PubMed=12093475;
RX   PubMed=20615970;
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (from parent cell line).
CC   Omics: Array-based CGH.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0279 ! GLC-4
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 18
//
RX   PubMed=1657425; DOI=10.1007/BF00685823;
RA   de Jong S., Zijlstra J.G., Mulder N.H., de Vries E.G.E.;
RT   "Lack of cross-resistance to fostriecin in a human small-cell lung
RT   carcinoma cell line showing topoisomerase II-related drug resistance.";
RL   Cancer Chemother. Pharmacol. 28:461-464(1991).
//
RX   PubMed=2163989; DOI=10.1002/ijc.2910460125;
RA   Hospers G.A.P., Meijer C., de Leij L.F.M.H., Uges D.R.A., Mulder N.H.,
RA   de Vries E.G.E.;
RT   "A study of human small-cell lung carcinoma (hSCLC) cell lines with
RT   different sensitivities to detect relevant mechanisms of cisplatin
RT   (CDDP) resistance.";
RL   Int. J. Cancer 46:138-144(1990).
//
RX   PubMed=2846161;
RA   Hospers G.A.P., Mulder N.H., de Jong B., de Leij L.F.M.H., Uges D.R.A.,
RA   Fichtinger-Schepman A.M.J., Scheper R.J., de Vries E.G.E.;
RT   "Characterization of a human small cell lung carcinoma cell line with
RT   acquired resistance to cis-diamminedichloroplatinum(II) in vitro.";
RL   Cancer Res. 48:6803-6807(1988).
//
RX   PubMed=12093475; DOI=10.1016/S0006-2952(02)00983-8;
RA   Fokkema E., Groen H.J.M., Helder M.N., de Vries E.G.E., Meijer C.;
RT   "JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to
RT   platinum-DNA adduct formation, glutathione levels and p53 status in
RT   human tumour cell lines with different sensitivities to cisplatin.";
RL   Biochem. Pharmacol. 63:1989-1996(2002).
//
RX   PubMed=20615970; DOI=10.1073/pnas.1008132107; PMCID=PMC2919980;
RA   Voortman J., Lee J.-H., Killian J.K., Suuriniemi M., Wang Y.-H.,
RA   Lucchi M., Smith W.I. Jr., Meltzer P.S., Wang Y.-S., Giaccone G.;
RT   "Array comparative genomic hybridization-based characterization of
RT   genetic alterations in pulmonary neuroendocrine tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:13040-13045(2010).
//